Physician profile
Robert M Cooper
NPI 1235159898
$6,745.68
in general payments reported to CMS, 2019-2025
40 companies · $1,184 in 2025
The $1,184 reported for 2025 was more than what 91% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,176 · 2020: $839 · 2021: $1,389 · 2022: $726 · 2023: $986 · 2024: $446 · 2025: $1,184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,958 · Travel and Lodging: $658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,957.60 |
| Travel and Lodging | $658.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $814.13 | 2023-2025 | Ams 700 Cxr Rte Kit, Ams 700 |
| Novo Nordisk INC | $807.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $729.04 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $658.81 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Astellas Pharma US INC | $393.80 | 2019-2021 | |
| Pfizer INC. | $360.58 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.19 | 2020-2024 | Jardiance |
| Sanofi-Aventis U.S. LLC | $322.86 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $308.70 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Abbvie INC. | $269.78 | 2021-2024 | Ubrelvy, Qulipta, Vraylar |
| Genzyme Corporation | $269.15 | 2019-2023 | |
| Amarin Pharma, INC. | $205.53 | 2021-2022 | |
| Glaxosmithkline, LLC. | $179.36 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $161.78 | 2019-2023 | Otezla, Repatha |
| Eisai INC. | $103.42 | 2021-2023 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.